Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
Authors
Keywords
Non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease, Dipeptidyl peptidase- 4, Sodium-glucose co-transporter 2, Inflammation, Fibrosis
Journal
Diabetology & Metabolic Syndrome
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-07-26
DOI
10.1186/s13098-016-0169-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
- (2016) Matthias Kern et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
- (2016) Yasushi Honda et al. PLoS One
- Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
- (2016) Chikara Komiya et al. PLoS One
- Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
- (2015) Shirong Qiang et al. Diabetology & Metabolic Syndrome
- Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis
- (2014) A. Liakos et al. DIABETES OBESITY & METABOLISM
- Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis
- (2014) Yun-A. Jung et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet
- (2014) Steven P Vickers et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
- (2013) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches
- (2013) Detlef Schuppan et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma
- (2013) Masato Fujii et al. Medical Molecular Morphology
- Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis
- (2013) Thomas Klein et al. Medical Molecular Morphology
- SGLT inhibitors in management of diabetes
- (2013) Abd A Tahrani et al. Lancet Diabetes & Endocrinology
- Nonalcoholic fatty liver disease and lipids
- (2012) Anthony S. Wierzbicki et al. CURRENT OPINION IN LIPIDOLOGY
- Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
- (2012) G. Musso et al. DIABETOLOGIA
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats
- (2012) James J. Devenny et al. Obesity
- Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity
- (2012) Matthias Kern et al. PLoS One
- Fatty acid synthase and liver triglyceride metabolism: Housekeeper or messenger?
- (2011) Anne P.L. Jensen-Urstad et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice
- (2011) J. Shirakawa et al. DIABETES
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea
- (2011) Yoshimasa Aso et al. Translational Research
- Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
- (2010) Christopher D. Williams et al. GASTROENTEROLOGY
- Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis
- (2010) Judith Ertle et al. INTERNATIONAL JOURNAL OF CANCER
- Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker
- (2010) Gábor Firneisz et al. PLoS One
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now